BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 8980181)

  • 1. PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears.
    Rozendaal L; Walboomers JM; van der Linden JC; Voorhorst FJ; Kenemans P; Helmerhorst TJ; van Ballegooijen M; Meijer CJ
    Int J Cancer; 1996 Dec; 68(6):766-9. PubMed ID: 8980181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
    Sherman ME; Lorincz AT; Scott DR; Wacholder S; Castle PE; Glass AG; Mielzynska-Lohnas I; Rush BB; Schiffman M
    J Natl Cancer Inst; 2003 Jan; 95(1):46-52. PubMed ID: 12509400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
    Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
    JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical value of digene hybrid capture HPV DNA testing in a referral-based population with abnormal pap smears.
    Recio FO; Sahai Srivastava BI; Wong C; Hempling RE; Eltabbakh GH; Piver MS
    Eur J Gynaecol Oncol; 1998; 19(3):203-8. PubMed ID: 9641214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.
    Wright TC; Denny L; Kuhn L; Pollack A; Lorincz A
    JAMA; 2000 Jan; 283(1):81-6. PubMed ID: 10632284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HPV testing in primary screening of older women.
    Cuzick J; Beverley E; Ho L; Terry G; Sapper H; Mielzynska I; Lorincz A; Chan WK; Krausz T; Soutter P
    Br J Cancer; 1999 Oct; 81(3):554-8. PubMed ID: 10507785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of risk factors and human papillomavirus (HPV) related pathogenetic mechanisms of CIN in HIV-positive and HIV-negative women. Study design and baseline data of the HPV-PathogenISS study.
    Branca M; Costa S; Mariani L; Sesti F; Agarossi A; di Carlo A; Galati M; Benedetto A; Ciotti M; Giorgi C; Criscuolo A; Valieri M; Favalli C; Paba P; Santini D; Piccione E; Alderisio M; De Nuzzo M; di Bonito L; Syrjänen K
    Eur J Gynaecol Oncol; 2004; 25(6):689-98. PubMed ID: 15597844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-risk HPV testing in women with borderline and mild dyskaryosis: long-term follow-up data and clinical relevance.
    Denise Zielinski G; Snijders PJ; Rozendaal L; Voorhorst FJ; Runsink AP; de Schipper FA; Meijer CJ
    J Pathol; 2001 Oct; 195(3):300-6. PubMed ID: 11673826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Human papillomavirus and screening for cervical cancer: state of art and prospects].
    Meijer CJ; Rozendaal L; Voorhorst FJ; Verheijen R; Helmerhorst TJ; Walboomers JM
    Ned Tijdschr Geneeskd; 2000 Aug; 144(35):1675-9. PubMed ID: 10981235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of high-risk human papillomavirus (HR-HPV) types 16 and 18 in healthy women with cytologically negative Pap smear.
    Arora R; Kumar A; Prusty BK; Kailash U; Batra S; Das BC
    Eur J Obstet Gynecol Reprod Biol; 2005 Jul; 121(1):104-9. PubMed ID: 15950365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Anal Cytology in Women with History of Abnormal Pap Smear, Cervical Intraepithelial Neoplasia, Cervical Cancer and High Risk HPV for Anogenital Dysplasia.
    Hosseini MS; Khosravi D; Farzaneh F; Ebrahimi A; Arab M; Ashraf Ganjoie T; Jamdar F; Moridi A; Chehrazi M
    Asian Pac J Cancer Prev; 2018 Nov; 19(11):3071-3075. PubMed ID: 30485943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Previous Papanicolaou and Hybrid Capture 2 human papillomavirus testing results of 5699 women with histologically diagnosed cervical intraepithelial neoplasia 2/3.
    Wu T; Chen X; Zheng B; Li J; Xie F; Ding X; Zeng Z; Zhao C
    J Am Soc Cytopathol; 2019; 8(4):206-211. PubMed ID: 31272603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.
    Ciotti M; Sesti F; Paba P; Benedetto A; Patrizi L; Criscuolo A; Piccione E; Branca M; Syrjänen K; Favalli C
    Eur J Gynaecol Oncol; 2004; 25(5):577-84. PubMed ID: 15493169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invader human papillomavirus (HPV) type 16 and 18 assays as adjuncts to HPV screening of cervical papanicolaou smears with atypical squamous cells of undetermined significance.
    Wong AK; Chan RC; Nichols WS; Bose S
    Cancer; 2009 Feb; 115(4):823-32. PubMed ID: 19127558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus and Papanicolaou tests to screen for cervical cancer.
    Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Johansson B; Forslund O; Hansson BG; Rylander E; Dillner J
    N Engl J Med; 2007 Oct; 357(16):1589-97. PubMed ID: 17942872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the human papillomavirus test and Papanicolaou smear as a second screening method for women with minor cytological abnormalities.
    Andersson S; Dillner L; Elfgren K; Mints M; Persson M; Rylander E
    Acta Obstet Gynecol Scand; 2005 Oct; 84(10):996-1000. PubMed ID: 16167918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.
    Verguts J; Bronselaer B; Donders G; Arbyn M; Van Eldere J; Drijkoningen M; Poppe W
    BJOG; 2006 Nov; 113(11):1303-7. PubMed ID: 16978225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.
    Manos MM; Kinney WK; Hurley LB; Sherman ME; Shieh-Ngai J; Kurman RJ; Ransley JE; Fetterman BJ; Hartinger JS; McIntosh KM; Pawlick GF; Hiatt RA
    JAMA; 1999 May; 281(17):1605-10. PubMed ID: 10235153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.